Kinase Inhibitor drugs compared

Compare all 43 Kinase Inhibitor drugs side by side, used for conditions such as leukemia, myeloid, accelerated phase, leukemia, myeloid, chronic-phase, gastrointestinal stromal tumors. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores. The highest-rated is danziten.

19 of 43 drugs in this class carry a pharmaranks safety score, ranging 60–72 out of 100 — computed from FDA recall records, not from reviews.

Rated against independent sources·Last updated July 30, 2026·How we rate

Top-rated kinase inhibitor: 1. Danziten · 2. Everolimus · 3. Ofev

Kinase Inhibitor drugs compared side by side, with pharmaranks' FDA recall-safety rating
Drug	Generic	Form	Status	Used for	Safety ratingFDA recall-based	Pharmacy pays
Danziten	Nilotinib Tartrate	Tablet	Prescription	Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase	72/100	—
Everolimus	—	Tablet	Prescription	—	72/100	$219
Ofev	Nintedanib Esylate	Capsule	Prescription	Idiopathic Pulmonary Fibrosis	72/100	$485
Sprycel	Dasatinib	Tablet	Prescription	Leukemia, Lymphoid, Leukemia, Myeloid	72/100	$810
Afinitor	Everolimus	Tablet	Prescription	—	70/100	$219
Calquence	Acalabrutinib	Capsule	Prescription	Lymphoma, Mantle-Cell	70/100	—
Cotellic	Cobimetinib Fumarate	Tablet	Prescription	Melanoma	70/100	—
Gleevec	Imatinib Mesylate	Tablet	Prescription	Leukemia, Lymphoid, Leukemia, Myeloid	70/100	$26
Kisqali	Ribociclib Succinate	Tablet	Prescription	Breast Neoplasms	70/100	—
Koselugo	Selumetinib Sulfate	Capsule	Prescription	Neurofibromatosis 1	70/100	—
Mekinist	Trametinib Dimethyl Sulfoxide	Solution	Prescription	Carcinoma, Non-Small-Cell Lung, Melanoma	70/100	—
Tabrecta	Capmatinib Hydrochloride	Tablet	Prescription	Carcinoma, Non-Small-Cell Lung	70/100	—

The safety rating column is unique to pharmaranks — an independent 0–100 score from FDA regulatory recall data. Higher is safer. Not medical advice.

Best kinase inhibitor by condition

for accelerated phase myeloid leukemia for chronic-phase myeloid leukemia for gastrointestinal stromal tumors for idiopathic pulmonary fibrosis for lymphoid leukemia for myeloid leukemia

Full ranking · 43 drugs

Frequently asked questions

What is the Kinase Inhibitor drug class?

Kinase Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 43 Kinase Inhibitor products, each independently rated.

Are all Kinase Inhibitor drugs the same?

No. Kinase Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Kinase Inhibitor drugs treat?

Per NIH RxClass drug-classification data, Kinase Inhibitor drugs are used for conditions including leukemia, myeloid, accelerated phase, leukemia, myeloid, chronic-phase, gastrointestinal stromal tumors, idiopathic pulmonary fibrosis, leukemia, lymphoid, leukemia, myeloid.

Which Kinase Inhibitor drug is best-rated?

By our independent rating, danziten currently ranks highest among Kinase Inhibitor drugs. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.

Sources: the Kinase Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class); how the class works is summarized from Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf. Ratings are pharmaranks’ independent FDA recall-safety analysis.